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ABSTRACT
Objective: Treatment of hemorrhagic stroke using tranexamic acid is still used in some hospitals, to prevent the occurrence of the complication 
called rebleeding. Rebleeding is an important cause of bad outcomes that result loss of consciousness and even death. The administration of the 
antifibrinolytic tranexamic acid in patients with hemorrhagic stroke can reduce the occurrence of rebleeding, but it also can increase poor outcome 
caused by cerebral ischemia that can worsen the patient’s condition.
Methods: This study used observational study design, cohort, prospective, and multicenter. The purpose of this study was to determine the effectiveness 
of the use of tranexamic acid in patients with hemorrhagic stroke. Statistical testing is done by analyzing the Glasgow coma scale (GCS) score on day 
1st, day 3rd, and day 7th between the treatment groups hemorrhagic stroke patients who received tranexamic acid therapy as antifibrinolytic therapy 
in Bethesda Hospital for 23 patients compared with a control group of patients hemorrhagic stroke who did not receive therapy as tranexamic acid 
antifibrinolytic therapy in the Dr. Sardjito Hospital for 23 patients.
Results: The statistical analysis of the independent t-test showed that there was no significant difference between the average GCS score of day 
1st (p=262), day 3rd (p=0.293), and day 7th (p=0.648) between treatment group and control group. The statistical analysis of the Mann-Whitney showed 
that there was not significant difference comparing the difference between the pre and post GCS score at treatment group and control group (p=0.158).
Conclusion: Administration of tranexamic acid in patients with hemorrhagic stroke (treatment group) gives the same clinical response compared to 
the patients who did not receive tranexamic acid therapy (control group) based on assessment of the GCS score.
Keywords: Hemorrhagic stroke, Tranexamic acid, Glasgow coma scale, Antifibrinolytic.
INTRODUCTION
Stroke is the second leading cause of death in the world in the age group 
>60 years and the fifth leading cause of death in the age group 15-59 years, 
the prevalence of stroke compared to other causes of death in the world 
is 10% or approximately 5.5 million people [1]. Stroke is a syndrome 
characterized by sudden focal or global functional impairment of the brain 
that growing very fast lasts more than 24 hrs (unless there is a surgical 
intervention or lead to death) caused by vascular disorders in the brain [2].
One of the therapy that is commonly used as the treatment of hemorrhagic 
stroke therapy in the hospital is tranexamic acid, to prevent rebleeding 
after hemorrhagic stroke. Tranexamic acid is an antifibrinolytic drug given 
to reduce bleeding, by preventing clot dissolution of blood clots due to 
bleeding [3]. Causes of poor manifestation of subarachnoid hemorrhage 
stroke are rebleeding, bleeding occurs from the dissolution of blood clots in 
blood vessels to rupture. Administration of antifibrinolytics is expected to 
reduce the risk of the re-bleeding event in hemorrhage stroke patients [4].
According Perdossi (Perhimpunan Dokter Spesialis Saraf Indonesia), 
giving tranexamic acid is recommended in patients with subarachnoid 
hemorrhage stroke to prevent rebleeding as antifibrinolytic therapy [5]. 
Intracerebral hemorrhage stroke patients are not recommended to be 
given tranexamic acid, intracerebral hemorrhage stroke patients is 
recommended to be given vitamin K, and fresh-frozen plasma for the 
treatment of hemolytic, but lately, prothrombin complex concentrates 
and recombinant factor VIIa have emerged as a potent therapy [6].
Some hospitals still provide tranexamic acid as antifibrinolytic to patients 
with hemorrhagic strokes either subarachnoid hemorrhage stroke or 
intracerebral hemorrhage stroke (personal communication, 2013). Thus, 
it requires further confirmation of the effectiveness of tranexamic acid 
administration as an antifibrinolytic in patients with hemorrhagic stroke 
with parameter score on the Glasgow coma scale (GCS).
METHODS
This study design was observational analytical study in cohort, collected 
the data prospectively from March 2014 until June 2014 at Bethesda 
Hospital (treatment group) and the Dr. Sardjito Hospital (control group), 
and then analyzed how the effects of tranexamic acid as antifibrinolytic 
use in patients with bleeding strokes against the prognosis of stroke by 
using the GCS for hospitalized for the first 7 days. The research protocol 
was approved by the Medical and Health Research Ethics Committee, 
Faculty of Medicine, Gadjah Mada University by numbers of ethics 
committee approval KE/FK/456/EC.
Subjects
Patient diagnosed with hemorrhagic stroke, hospitalized at Bethesda 
Hospital and the Dr. Sardjito Hospital. The exclusion criteria are patients 
with impaired blood clotting function, patients who suffered repeated 
strokes, patients were taken to the hospital >24 hrs after the attack, 
patients were followed up by surgery as a bleeding stroke proceeding, 
and patients who cannot be judged the initial conditions before getting 
tranexamic acid therapy, the deadline assessment of initial patients’ 
condition were within 24 hrs after admission to hospital.
Sampling size
The minimum sample size for evaluating hypertension control 
within the population received therapy was 22 subjects. The sample 
Research Article
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10s2.19498
95
Special Issue (May)
 Setiawan et al. 













β=4×α=0.2; If β=0.2 so Zβ=0.842
µ1−µ2=Clinical judgement=0.5
Data collection
The data will be retrieved from the files of patient includes demographic 
data of patients (age, gender), comorbidities of the patients (diabetes 
mellitus and dyslipidemia), as well as the entire management of therapy 
that patients get during hospitalization on diagnosis of hemorrhagic 
stroke and patient GCS progress.
Data analysis
Data analysis was carried out in broad outline, namely:
1. The statistical test t unpaired (independent sample t-test) if the data 
were normally distributed or Mann–Whitney test if data distribution 
is not normal to compare the score on the GCS between the treatment 
groups with the tranexamic acid group and without tranexamic acid 
therapy on day −1, day 3, and day 7.
2. The same test performed to compare the difference in scores GCS 
day 1 and day 7 of tranexamic acid therapy group (treatment group) 
receiving no treatment with tranexamic acid group (the control group).
All statistical tests were statistically significant when p<0.05.
RESULTS
The basic characteristic of the study subjects was obtained through 
descriptive analysis. A total of 46 patients with hemorrhagic stroke 
who first diagnosed with hemorrhagic stroke, not getting surgery for 
the treatment of his/her hemorrhagic stroke, length of hospitalization 
of at least 7 days, onset of <24 hrs, treated with tranexamic acid in 
Bethesda Hospital (treatment group), and did not get tranexamic 
acid in Dr. Sardjito Hospital (the control group) as an antifibrinolytic 
therapy that met inclusion included in the descriptive analysis. Data 
taken from March 2014 through June 2014 prospectively. Data taken 
the basic characteristics such as age, sex, and comorbidities (diabetes 
mellitus and dyslipidemia) are used as baseline data to see the profile 
of research subjects (Table 1).
The basic characteristics such as frequency proportion to age, sex, 
and comorbidities of diabetes mellitus was no difference between 
the treatment group and the control group, while the proportion of 
dyslipidemia comorbidities differ between the treatment group and the 
control group.
The basic characteristic of which is a risk factor that can influence the 
outcome score on the GCS are temperature and blood pressure. From 
the results obtained Mann–Whitney test p=0.70, so it can be concluded 
that there is no average difference between the average temperature of 
the patient for 7 days in the treatment group and the control group were 
significant (p>0.05: There are no significant differences between groups 
of data that tested). With this test, the temperature data did not differ 
significantly between the treatment and control groups that did not affect 
the score on the GCS between the two groups. The test results independent 
t-test for blood pressure, the results obtained are p=0.066 (systole) and 
p=0.468 (diastole), so it can be concluded that there is no significant 
difference between average blood pressure systolic and diastolic for 7 days 
in group control and treatment groups were significant (p>0.05). Blood 
pressure did not affect the score on the GCS between the two groups.
Temperature can affect patients prognosis with stroke, high 
temperatures for 37.5°C that occurred during the first 24 hrs was found 
in 83% of patients lead to bad outcomes associated with the expansion 
of ventricular hemorrhage [7].
A decrease in blood pressure in bleeding stroke is to prevent the expansion 
of bleeding, especially when bleeding from the aneurysm rupture. In 
primary intracerebral haemorrhage stroke where a specific blood vessel 
abnormality is not found, the risk of hemorrhage expansion as a smaller 
rise in blood pressure and should be considered the possibility of cerebral 
ischemia if there is a decrease in blood pressure [7] (Table 2).
Profile of treatment cannot be analyzed since each patient has a 
different treatment depending on clinical condition. Furosemide and 
mannitol therapy cannot be analyzed because there are differences 
in the treatment group and the control group was due to differences 
in standard of medical services and clinical condition of the patient 
(increase in intracranial pressure).
Of all, the data normality test average GCS score in the treatment 
group and the control group data distribution is not normal, then the 
Table 1: The baseline characteristics of hemorrhagic stroke patients in the treatment group, and the control group in March 2014 
through June 2014
Variable Treatment group (n=23) Control group (n=23) p value
n (%) n (%)
Age (years)
>70 5 (21.74) 2 (8.70) 0.84
61-70 6 (26.09) 8 (34.78)
51-60 7 (30.43) 8 (34.78)
40-50 4 (17.39) 4 (17.39)
<40 1 (4.35) 1 (4.35)
Sex
Male 14 (60.70) 14 (60.70) 0.00
Female 9 (39.30) 9 (39.30)
Diabetes melitus
Yes 11 (47.83) 10 (43.48) 0.048
No 12 (52.17) 13 (56.52) 0.04
Dyslipidemia
Yes 12 (52.17) 9 (39.13) 0.43
No 11 (47.83) 14 (60.87) 0.36
The average temperature of hemorrhagic stroke patients for 7 days 36.8±0.32 36.65±0.59 0.07
Systolic blood pressure an average of 7 days 142.23±16.69 152.71±20.73 0.07
Diastolic blood pressure on average over 7 days 85.34±8.67 87.40±10.31 0.47
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comparison of data between the two hospitals can use statistical test 
of Mann–Whitney. Table 3 shows the results of statistical analysis using 
Mann–Whitney, of the test results, showed there was no significant 
difference between the average score of GCS day 1, day 3 and day 7 in 
both the treatment group and the control group. From Table 4, it can 
be seen the difference in score on the GCS day 1 and day 7 between 
the treatment group and the control group, which is obtained from a 
reduction in GCS score on day 7 with a GCS score of day 1. From testing 
normality, the data difference GCS score in the control group was 
not normal, then tested the Mann–Whitney statistic to compare the 
difference in score GCS day 1 and day 7 between the treatment group 
and the control group.
Statistical tests in Table 4 showed no significant difference between 
comparing the difference in GCS score day 1 and day 7 between 
the treatment group and the control group, so it can be deduced 
administration of tranexamic acid in patients with hemorrhagic 
stroke is not effectively assessed from clinical conditions together 
with hemorrhage stroke patients who did not receive tranexamic acid 
therapy based on the difference in score on the GCS between day 1 
and day 7 between the treatment group and the control group were 
consistent with the hypothesis of the study.
DISCUSSION
From this study showed that administration of tranexamic acid that 
does not give better improvement for hemorrhage stroke based on GCS 
score.
In the pilot study by Sprigg et al., administration of tranexamic acid 
in patients with intracerebral hemorrhage stroke as antifibrinolytic 
therapy does not provide a significant difference to the placebo group 
at day 90 based on the Modified Rankin Scale, Barthel Index, and 
death [8]. Some studies support this result, giving tranexamic acid 
in patients with subarachnoid hemorrhage stroke as antifibrinolytic 
therapy revealed no significant differences in the parameters of the 
Glasgow outcome scale (GOS) between tranexamic acid and placebo 
groups [9-11].
Antifibrinolytic therapy in subarachnoid hemorrhage stroke for 4 weeks 
after the hemorrhage does not provide better outcomes compared 
to placebo due to increased ischemic events despite the downturn of 
rebleeding [12]. According to the Cochrane systematic review of 2008, 
the use of tranexamic acid as antifibrinolytic therapy in aneurysm 
subarachnoid hemorrhage stroke patients does not provide clinical 
improvement, but it can give poor results that are cerebral ischemia [4].
This study, however, still have some limitations. Further, studies are 
needed for a variety of variables that may influence the clinical score 
on the GCS in patients with bleeding; such patients receive treatment, 
initial GCS type of bleeding stroke, hemorrhage volume, site of bleeding, 
patients received treatment, and the type of treatment the patient 
received. On the other hand, further research is also needed with a 
longer period to see the outcome, additional criteria such as motor 
movements, patient outcomes and scale of the GOS, the incidence of 
rebleeding and ischemic events at the rupture site.
The use of tranexamic acid as antifibrinolytic therapy in patients with 
hemorrhagic stroke needs to be reconsidered because of the research 
Table 2: List of drugs for the treatment of hemorrhagic stroke patients who used the control group and the treatment group during 
hospitalization 7 days
No. Drug classification Drug Treatment goup (n=23) Control group (n=23)
1. Hemostatic Stoblet® 8 0
Vitamin K 16 0
2. Osmotic agent Manitol 5 21











4. Neuroprotective Piracetam 5 6
Citicoline 7 22
Mecobalamin 2 4
5. Corticosteroid Dexamethasone 1 2
6. Antipyretic analgetic Parasetamol 5 14
Ibuprofen 1 0






8. Antihiperlipidemia Atrovastatin 3 0
Simvastatin 0 2
Gemfibrozil 0 1
9. Antigout Allopurinol 1 2
HCT: Hydrochlorothiazide
Table 3: Analysis score on the GCS on day 1, day 3, and day 7 
between the treatment group and the control group
Day Average GCS score of 
treatment groups
Average GCS score of 
control group
p‑value
Day 1 10.57 11.70 0.279
Day 3 11.48 12.43 0.295
Day 7 12.43 11.96 0.73
GCS: Glasgow coma scale
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does not provide a better clinical response compared with patients who 
did not get the bleeding stroke tranexamic acid therapy.
CONCLUSION
Giving tranexamic acid in patients with hemorrhagic stroke as 
antifibrinolytic therapy is not effective assessed from similar clinical 
responses to patients with hemorrhagic stroke who do not get 
treatment tranexamic acid based on ratings GCS on day 1, day 3, and 
day −7.
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Table 4: Analysis of differences in score on the GCS on day 1 and day 7 between the treatment group and the control group
Patient Treatment group Control group p value
Day 1 Day 7 GCS difference day 1 and the 7th Day 1 Day 7 GCS difference day 1 and the 7th
Patient 1 8 8 0 15 15 0 0.158
Patient 2 15 15 0 15 15 0
Patient 3 15 15 0 15 15 0
Patient 4 14 15 1 15 15 0
Patient 5 10 15 5 10 15 5
Patient 6 7 15 8 14 9 −5
Patient 7 6 8 2 12 15 3
Patient 8 10 8 −2 9 9 0
Patient 9 6 15 9 7 4 −3
Patient 10 10 12 2 13 15 2
Patient 11 8 9 1 15 15 0
Patient 12 7 10 3 14 9 −5
Patient 13 9 15 6 15 10 −5
Patient 14 10 3 −7 12 13 1
Patient 15 15 15 0 14 15 1
Patient 16 6 10 4 15 15 0
Patient 17 14 14 0 15 15 0
Patient 18 10 15 5 8 12 4
Patient 19 15 15 0 6 10 4
Patient 20 15 15 0 9 10 1
Patient 21 11 9 −2 9 4 −5
Patient 22 12 15 3 8 9 1
Patient 23 10 15 5 4 11 7
Average 10.57 12.43 1.87±3.55 11.70 11.96 0.26±3.24
GCS: Glasgow coma scale
